Phase 1 trial of TSR-022 in combination with an anti-PD-1 antibody, TSR-042, in solid tumour patients
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2018
At a glance
- Drugs TSR 022 (Primary) ; TSR 042 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms AMBER
- 27 Feb 2018 According to a TESARO Inc. media release, this trial is enrolling three tumor specific cohorts and initial data is expected in 2H 2018.
- 07 Nov 2017 According to a TESARO Inc. media release, the company expects to present initial data from the combination study in 2018.
- 07 Nov 2017 Data from the monotherapy, dose-escalation portion of this trial will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting 2017, according to a TESARO Inc. media release.